Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Helpful Links 1 Plan names are shown in the top right corner of your member ID card
Regulatory history: Sermorelin was FDA-approved in 1997 under the brand name Geref for the treatment of growth hormone deficiency in children
WADA-prohibited at all times for in-competition and out-of-competition athletes
SURMOUNT-1 trial data showed mean weight reductions of 15.0% (5mg), 19.5% (10mg), and 20.9% (15mg) at 72 weeks, compared to 3.1% with placebo
Potential tumor promotion : Given its angiogenic properties, there is theoretical concern it could contribute to tumor growth or neovascularization in certain contexts
No adverse reactions were detected when dosing at 25 nmol/kg or 75 nmol/kg
